3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
2
Spondylitis, Ankylosing
1
Signs and Symptoms
1
Psoriasis
1
Nutrition Disorders
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Insulin Resistance
1
Inflammatory Bowel Diseases
1
Glioma
1
Gastroparesis
1
Feeding and Eating Disorders
1
Esophageal Neoplasms
1
Epilepsy
1
Dumping Syndrome
1
Diarrhea
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Sirolimus
4
Everolimus
3
Anticonvulsants
2
ziprasidone
1
perampanel
1
enzalutamide
1
clevidipine
1
brivaracetam
1
Zolpidem
1
Warfarin
1
Vigabatrin
1
Vecuronium Bromide
1
Vancomycin
1
Tranexamic Acid
1
Tobramycin
1
Therapeutic Touch
1
Temozolomide
1
Surgical Procedures, Operative
1
Sulfasalazine
1
Spironolactone
1
Sevoflurane
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Registries
1
Radiotherapy
1
Propofol
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Epilepsy
×
Sulfasalazine
×
Clear all
NCT05664464
2024-05-10
GLUGLIO
University of Zurich
Phase 1/2
Recruiting
120 enrolled